SAN FRANCISCO & LEUVEN, Belgium–(BUSINESS WIRE)–Unlearn®, a pacesetter in AI options for scientific trials, at this time introduced outcomes from a collaboration with remynd, a Belgium-based biotech firm growing remedies for neurodegenerative ailments. The outcomes have been shared on the 2025 Alzheimer’s & Parkinson’s Drug Improvement Summit in Boston.
The collaboration centered on remynd’s Part 2a scientific trial of REM127, an investigational, first-generation small molecule remedy focusing on septins in sufferers with mild-to-moderate Alzheimer’s Illness (AD). The research enrolled a restricted variety of contributors and measured modifications in AD biomarkers over a brief remedy window.
Unlearn supported the research by making use of its Alzheimer’s Illness-specific Digital Twin Generator (AD DTG)—a proprietary machine studying mannequin educated on knowledge from greater than 26,000 contributors throughout landmark AD datasets reminiscent of ADNI, CPAD, NACC, and EPAD. The AD DTG makes use of every participant’s baseline knowledge to forecast their scientific and biomarker trajectories below commonplace care, producing a “digital twin” for each particular person within the trial.
These digital twins served as individualized comparators, offering an extra layer of proof to assist interpret modifications noticed within the handled inhabitants. This method is especially useful in early-phase research the place small pattern sizes restrict the flexibility to attract conclusions utilizing conventional statistical strategies alone.
“It is a highly effective instance of how digital twins might help unlock insights from small research,” mentioned Steve Herne, CEO of Unlearn. “Our collaboration with remynd helped strengthen the proof behind REM127 and demonstrated the worth of utilizing AI to assist smarter, quicker scientific analysis.”
“The collaboration with Unlearn and the ensuing knowledge additional will increase our confidence in our pioneering method in the direction of reaching symptomatic aid and illness modification in Alzheimer’s. This can assist our efforts to advance an optimized second-generation remedy,” mentioned Gerard Griffioen, Ph.D., CSO of remynd. “Digital twins supply a brand new lens for decoding biomarker traits over time—particularly in early-stage trials the place each knowledge level issues.”
For extra info, go to www.unlearn.ai or observe us on LinkedIn and X/Twitter.
